Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

DiCE

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

Sanofi reception

Sanofi wins EU approval for second MS drug in a month

EC approves Lemtrada weeks after Aubagio gets greenlight

- PMLiVE

Sanofi pulls Lyxumia’s US filing

Says will resubmit diabetes drug for FDA approval in 2015

- PMLiVE

Sanofi plans its mobile diabetes future

Next phase of iBGStar project will focus on wider connectivity

China flag thumb

Sanofi drawn into Chinese corruption probe

Joins GSK, UCB, AZ , Lilly, Novo and Lundbeck as companies under scrutiny

- PMLiVE

Sanofi vaccine against GI ‘superbug’ starts phase III

Aims to protect against Clostridium difficile

Sanofi reception

FDA panel backs OTC use of Sanofi’s allergy drug

Says Nasacort AQ can be sold without prescription

China flag thumb

Sanofi and Lilly also visited by Chinese authorities

Follows GSK bribery allegations

Sanofi reception

Sanofi cuts forecasts but says worst effects of patent cliff have passed

Sales continue to fall on generic competition and mismanagement in Brazil affects emerging markets

- PMLiVE

Executive changes at Sanofi

Genzyme CEO Meeker becomes executive VP and Hellmann joins to lead animal health

Sanofi Israel crowdsources new diabetes app

Collaborates with online patient network Camoni

Sanofi reception

Sanofi wins Japanese approval for diabetes drug Lyxumia

Becomes first treatment of its class licensed in combination with basal insulin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links